论文部分内容阅读
目的观察并探讨奥扎格雷钠与尤瑞克林联用治疗急性脑梗死临床效果及安全性。方法选取内蒙古自治区人民医院2010年1月至2011年6月收治急性脑梗死患者50例,随机分为两组,其中对照组25例,采用奥扎格雷钠静脉滴注治疗;实验组25例,在对照组治疗基础上,加用尤瑞克林静脉滴注治疗;疗程均为4周,治疗结束后评价临床效果及安全性。结果对照组患者总有效例数为15例,总有效率为60.0%;实验组患者总有效例数为22例,总有效率为88.0%;实验组患者治疗总有效率明显高于对照组,两组间比较差异有统计学意义(P<0.05);治疗前对照组与实验组患者神经功能缺损评分比较差异无统计学意义(P>0.05);治疗后实验组患者神经功能缺损评分明显低于对照组,两组间比较差异统计学意义(P<0.05);同时两组患者治疗前后舒张压与收缩压组内比较差异也有统计学意义(P<0.05);对照组患者治疗过程中未出现不良反应;实验组患者出现头痛1例,低血压1例,降低滴速后均自行缓解。结论奥扎格雷钠与尤瑞克林联用治疗急性脑梗死临床效果确切,治疗有效率高,能够有效改善神经功能缺损症状,且不良反应较少,具有临床推广使用价值。
Objective To observe and discuss the clinical effect and safety of sodium ozagrel combined with eruciclovir in the treatment of acute cerebral infarction. Methods Fifty patients with acute cerebral infarction in People’s Hospital of Inner Mongolia Autonomous Region from January 2010 to June 2011 were randomly divided into two groups, of which 25 cases in the control group were treated with intravenous Ozagrel sodium; 25 cases in the experimental group, In the control group based on the treatment, plus intravenous infusion of uricase; treatment were 4 weeks after the end of treatment to evaluate the clinical effect and safety. Results The total number of patients in the control group was 15 and the total effective rate was 60.0%. The total number of patients in the experimental group was 22 and the total effective rate was 88.0%. The total effective rate of the experimental group was significantly higher than that of the control group, The difference between the two groups was statistically significant (P <0.05). There was no significant difference in neurological deficit score between the control group and the experimental group before treatment (P> 0.05). After treatment, the score of neurological deficit in the experimental group was significantly lower In the control group, the difference between the two groups was statistically significant (P <0.05); at the same time, the difference between the diastolic blood pressure and the systolic blood pressure before and after treatment in the two groups was also statistically significant (P <0.05); in the control group, There was an adverse reaction. One patient had headache in the experimental group and one patient had hypotension. Conclusion The combination of ozagrel sodium and ureclin in the treatment of acute cerebral infarction has definite clinical effect, high effective rate of treatment, can effectively improve the symptoms of neurological deficits with less adverse reactions, and has clinical value of popularization and use.